- Investing Ideas
- U.K. Pharmaceuticals & Biotech Undervalued Stocks Based On Cash Flows
U.K. Pharmaceuticals & Biotech Undervalued Stocks Based On Cash Flows
Results
3
2 new
Companies with promising cash flow potential yet trading below their fair value, as determined by SWS DCF valuation, signaling opportunity for value-oriented investors.
3 companies
AstraZeneca
Market Cap: UK£193.5b
A biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines.
New
AZN
UK£122.34
7D
1.5%
1Y
3.0%
Diaceutics
Market Cap: UK£121.8m
A diagnostic commercialization company, provides data, data analytics, and implementation services for pharma and biotech companies.
New
DXRX
UK£1.48
7D
3.1%
1Y
7.3%
hVIVO
Market Cap: UK£44.7m
Operates as a full-service early specialist contract research organisation in the United Kingdom, Europe, and North America.
HVO
UK£0.064
7D
-3.0%
1Y
-36.0%